Delivery Order SPE2DB20D2104-SPE2DB25FMALR

Award Date 10/15/24
Potential Completion Date 11/5/24
Potential Value $9.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of LYNPARZA 100 MG TABLET UU 120S. The contract has a firm fixed price of $21,039.24 and a completion date of June 4, 2025. AmerisourceBergen Drug Corp is the prime contractor, and the contract is not set aside. The company holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider, for the supply of LYNPARZA 150 MG TABLET. The contract has a firm fixed price of $10,567.60 and a period of performance through July 15, 2025. It is not set aside for any particular business type. AmerisourceBergen Drug Corporation holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,519.62, is for the delivery of Lynparza 100 mg tablets. The award is not set-aside and is a firm fixed-price delivery order contract. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00,...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is a Delivery Order for the medication LYNPARZA 150 MG TABLET UU 60S, with a ceiling value of $20,998.68 and a completion date of July 15, 2025. The contract is a Firm Fixed Price agreement and is not a set-aside. AmerisourceBergen Drug Corp has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The $39,357.76 firm fixed price delivery order is for the pharmaceutical product Lynparza 100 mg tablets. The contract has an ultimate completion date of June 12, 2024. Amerisourcebergen, a major supplier of pharmaceuticals and medical supplies to the federal government, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
This federal contract award is a Delivery Order valued at $10,567.60 made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LYNPARZA 150 MG TABLET, a prescription medication, with a performance period through July 1, 2025. This contract is not set aside for any specific business type. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $10,499.34 firm-fixed-price contract is for the delivery of Lynparza 150 mg tablets over a period ending on May 29, 2025. This contract is not a set-aside and is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, which provides a comprehensive global pharmaceutical support vehicle...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 150 mg Lynparza tablets, a prescription medication. The fixed-price contract has a ceiling value of $31,702.80 and a performance period ending on July 1, 2025. The contract is not set-aside and represents open competition. AmerisourceBergen Drug Corp holds a significant...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a total ceiling value of $10,567.60 and is for the delivery of LYNPARZA 150 MG TABLET UU 120S, a pharmaceutical product. The contract is a firm fixed-price delivery order with a period of performance through February 18, 2025. The place of performance is Conshohocken, Pennsylvania. This contract...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp. The $197,103.10 firm-fixed-price contract is for the supply of LYNPARZA 150 MG TABLET UU 120S, a pharmaceutical product. The award has an ultimate completion date of August 14, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded numerous federal contracts and Indefinite Delivery Contracts (IDCs) by various defense and civilian agencies to...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB25FMALR
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Lynparza 150 mg tablets. The $9,870.87 firm-fixed-price contract has a completion date of November 5, 2024. It is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024 for similar medical products and prescription drugs.

Generated 2/27/25, 1:29 PM